TRT and Fertility: How Testosterone Therapy Affects Sperm Production

Why TRT Suppresses Fertility

Exogenous testosterone signals the hypothalamus to reduce gonadotropin-releasing hormone (GnRH) output. Within 2 to 4 weeks, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) fall to near-undetectable levels [1]. LH normally drives Leydig cells to produce intratesticular testosterone (ITT) at concentrations 50 to 100 times higher than serum levels. FSH stimulates Sertoli cells, which nurse developing sperm through their 74-day maturation cycle.

When both signals disappear, ITT collapses. Sertoli cells lose their primary growth factor. The result is predictable and dose-dependent: spermatogenesis slows, then stops. A 2006 study in the Journal of Clinical Endocrinology & Metabolism found that 65% of men receiving testosterone enanthate 200 mg every 2 weeks became azoospermic within 6 months [2]. The remaining 35% showed severe oligospermia, with counts well below the 15 million/mL threshold the WHO defines as normal.

This is not a rare side effect. It is the expected pharmacologic outcome.

Timeline: How Fast Does Sperm Count Drop?

Suppression follows a consistent pattern. LH and FSH decline within the first 2 to 4 weeks of starting any testosterone formulation, whether injections, gels, or pellets [1]. Sperm counts begin falling by week 6 to 8. By month 3, most men show counts below 1 million/mL. Full azoospermia typically appears between months 4 and 6.

The speed of suppression does not depend much on the delivery method. Testosterone cypionate injections, transdermal gels, and subcutaneous pellets all suppress the HPG axis with comparable timelines [3]. Higher doses accelerate suppression slightly, but even physiologic replacement doses (100 mg/week of testosterone cypionate) reliably reduce sperm output to subfertile or infertile ranges.

One critical point: TRT should never be used as a reliable contraceptive. Roughly 5 to 10% of men retain low-level spermatogenesis on TRT, enough to father a child [2]. The suppression is profound but not absolute in every individual.

Can Fertility Recover After Stopping TRT?

Recovery happens for most men, but the timeline varies widely. A landmark review by Patel et al. (2019) in Fertility and Sterility reported that the median time to recovery of spermatogenesis after discontinuing exogenous testosterone was approximately 6 months, with 67% of men recovering within 6 to 12 months and 90% recovering within 12 to 24 months [4].

However, "recovery" does not always mean "back to baseline." Some men, particularly those who used testosterone for years or who had borderline sperm parameters before starting, may never fully recover prior counts [4]. Age compounds this risk. A 40-year-old who used TRT for 5 years faces a longer and less certain recovery than a 28-year-old who used it for 8 months.

The American Urological Association (AUA) 2018 guidelines explicitly recommend against prescribing TRT to men who are planning fertility in the near term [5]. This recommendation has not changed through the 2024 update cycle.

Fertility-Preserving Alternatives to Standard TRT

Men with symptomatic hypogonadism who want to maintain fertility have several evidence-based options. These are not speculative treatments. Each has published trial data supporting both testosterone elevation and sperm preservation.

Clomiphene citrate (off-label) blocks estrogen receptors at the hypothalamus, tricking the brain into producing more GnRH, LH, and FSH. A 2015 study by Wheeler et al. in the Journal of Urology showed that clomiphene 25 to 50 mg every other day raised serum testosterone by an average of 200 to 300% while maintaining or improving sperm counts in hypogonadal men [6]. Side effects include mood changes, visual disturbances (rare), and elevated estradiol requiring monitoring.

Human chorionic gonadotropin (hCG) mimics LH, stimulating Leydig cells directly to produce intratesticular testosterone. When co-administered with TRT, hCG at doses of 500 IU three times per week has been shown to maintain ITT at levels sufficient for ongoing spermatogenesis [7]. A study by Coviello et al. (2005) demonstrated that concurrent hCG preserved ITT during testosterone administration in a dose-dependent manner [7]. This approach does not fully preserve sperm counts to pre-TRT levels, but it significantly reduces the depth of suppression.

Enclomiphene, the trans-isomer of clomiphene, is under investigation as a more targeted SERM with fewer estrogenic side effects. Preliminary data from phase 2 trials showed testosterone increases comparable to clomiphene with potentially better tolerability, though it remains unapproved by the FDA as of May 2026 [8].

Semen cryopreservation before initiating TRT gives men a biological safety net. The AUA recommends discussing sperm banking with all men of reproductive age before starting testosterone therapy [5]. Modern cryopreservation maintains sperm viability for decades when stored properly.

The hCG + TRT Protocol: How Clinicians Manage Both Goals

For men who need TRT for severe symptoms but want to keep the door open for fertility, the combination of testosterone cypionate plus hCG has become the most common clinical approach. The typical protocol involves testosterone cypionate 100 to 200 mg per week (split into two or three subcutaneous or intramuscular injections) plus hCG 500 IU subcutaneously three times per week [7].

Monitoring is essential. Clinicians check semen analysis at baseline, 3 months, and 6 months. Serum testosterone, estradiol, LH, FSH, and hematocrit panels should be drawn every 3 to 6 months during the first year [5]. If sperm counts fall below the patient's target despite hCG co-therapy, options include adding low-dose FSH (75 IU every other day) or transitioning off exogenous testosterone entirely in favor of clomiphene or hCG monotherapy.

One limitation: hCG availability has fluctuated since the FDA's 2020 enforcement of the Biologics Control Act, which reclassified hCG as a biologic. Compounded hCG became harder to obtain, though branded products (Pregnyl, Novarel) remain available. Patients should verify their pharmacy source before committing to this protocol.

Erythrocytosis: The Most Common Lab Side Effect of TRT

While fertility suppression receives less attention than it deserves, erythrocytosis (elevated hematocrit) is the most frequently encountered laboratory abnormality during TRT [9]. Testosterone stimulates erythropoietin production in the kidneys and acts directly on bone marrow progenitor cells, increasing red blood cell mass.

A meta-analysis by Bachman et al. (2010) found that testosterone therapy increased hematocrit by an average of 3.2% across trials, with up to 20% of men on injectable testosterone exceeding hematocrit levels of 54% [9]. Hematocrit above 54% raises the risk of venous thromboembolism, stroke, and myocardial infarction.

The Endocrine Society Clinical Practice Guideline (2018) recommends checking hematocrit at baseline, 3 to 6 months after starting TRT, and annually thereafter [10]. If hematocrit exceeds 54%, options include dose reduction, switching from injections to gels (which produce smaller hematocrit increases), increasing injection frequency to reduce peak levels, therapeutic phlebotomy, or temporary discontinuation.

Erythrocytosis risk is highest with intramuscular injections dosed every 2 weeks, where supraphysiologic peaks in the first 3 to 4 days drive excessive erythropoiesis. Splitting the same weekly dose into two or three smaller injections flattens the pharmacokinetic curve and reduces this risk [10].

TRT and Prostate Cancer Risk: What Current Evidence Shows

The fear that testosterone causes prostate cancer traces back to Huggins and Hodges' 1941 Nobel Prize-winning work demonstrating that castration shrank metastatic prostate tumors [11]. For decades, clinicians extrapolated this finding to mean that adding testosterone must fuel cancer growth. That extrapolation lacks supporting evidence.

The TRAVERSE trial (2023), the largest randomized controlled trial of TRT safety to date (N=5,246 men, median follow-up 33 months), found no statistically significant increase in prostate cancer incidence among men randomized to testosterone gel versus placebo (hazard ratio 0.97, 95% CI 0.52 to 1.80) [12]. The trial was designed primarily to assess cardiovascular events, but prostate cancer was a prespecified secondary endpoint.

A 2016 meta-analysis by Boyle et al. in BMJ pooled data from 26 randomized controlled trials and found no association between testosterone therapy and increased prostate cancer diagnosis (OR 0.87, 95% CI 0.30 to 2.50) [13].

The Endocrine Society does not consider a history of successfully treated prostate cancer to be an absolute contraindication to TRT, though it recommends caution and urologic co-management [10]. Men with untreated or active prostate cancer should not receive TRT.

Prostate-specific antigen (PSA) monitoring remains standard: check PSA at baseline, 3 to 6 months, and annually. A rise exceeding 1.4 ng/mL within 12 months or an absolute value above 4.0 ng/mL warrants urologic referral, regardless of TRT status [10].

TRT and Benign Prostatic Hyperplasia (BPH)

Testosterone is converted to dihydrotestosterone (DHT) by 5-alpha reductase in prostate tissue, and DHT is the primary androgen driving prostate growth. This biochemical fact raises a reasonable question: does TRT worsen BPH symptoms?

Clinical trial data suggests the effect is minimal at physiologic replacement doses. A 2018 systematic review by Pearl et al. found that TRT at standard doses did not significantly worsen lower urinary tract symptoms (LUTS) as measured by International Prostate Symptom Score (IPSS) and, in some studies, modestly improved them [14]. The likely explanation is that obesity, metabolic syndrome, and estrogen excess (all features of hypogonadism) are independent drivers of BPH, and treating the underlying testosterone deficiency may address these contributing factors.

Men with severe, untreated BPH causing urinary retention should have their urologic condition stabilized before initiating TRT. For men with mild to moderate LUTS already on alpha-blockers or 5-alpha reductase inhibitors, TRT can typically be started with appropriate monitoring of IPSS and post-void residual volumes [10].

Broader TRT Side Effects: A Clinical Overview

Beyond fertility suppression, erythrocytosis, and prostate considerations, men starting TRT should be aware of the following side effects.

Acne and oily skin affect roughly 15 to 25% of men, particularly in the first 3 to 6 months. The mechanism involves DHT-mediated stimulation of sebaceous glands. Most cases are mild and responsive to topical retinoids or benzoyl peroxide [10].

Testicular atrophy occurs because exogenous testosterone suppresses LH, removing the primary trophic stimulus for Leydig and Sertoli cell maintenance. Testicular volume typically decreases by 20 to 30% over the first year [1]. This is partially preventable with concurrent hCG therapy.

Gynecomastia results from aromatization of testosterone to estradiol in adipose tissue. Men with higher body fat percentages face greater risk. Monitoring estradiol levels and maintaining body fat below 25% reduces incidence. Anastrozole 0.5 mg twice weekly is sometimes prescribed when estradiol exceeds 40 to 50 pg/mL, though routine aromatase inhibitor use is not recommended by current guidelines [10].

Mood and behavioral changes are reported by some men, though the TRAVERSE trial found no significant difference in rates of depression, anxiety, or aggression between testosterone and placebo groups [12]. Supraphysiologic doses (above the therapeutic range) carry higher behavioral risk than replacement doses.

Sleep apnea may worsen in predisposed men. The Endocrine Society lists severe untreated obstructive sleep apnea as a relative contraindication to TRT initiation [10]. Men with suspected sleep-disordered breathing should undergo polysomnography before starting therapy.

Making an Informed Decision

A man considering TRT should have a semen analysis and a candid conversation about reproductive plans before the first injection. If children are part of the picture now or within the next few years, clomiphene citrate or hCG monotherapy can raise testosterone while keeping sperm production intact. If TRT is clinically necessary, concurrent hCG at 500 IU three times per week preserves partial spermatogenesis during treatment. Baseline hematocrit, PSA, and lipid panels set the monitoring foundation, with follow-up labs at 3, 6, and 12 months [5][10].